Sheba medical center became the first Israeli facility to receive permission from Medtronic International to train medical professionals on MICRA pacemaker implants.

Sheba medical center became the first Israeli facility to receive permission from Medtronic International to train medical professionals on MICRA pacemaker implants

Share This Post

RAMAT GAN, Israel – June, 2022 – Sheba Medical Center, Israel’s largest medical center and a Newsweek top-10 ranked world’s best hospital for the last four years, announced today that it has been authorized by Medtronic International to provide training on MICRA pacemaker implants for experts in arrythmia treatment.

Sheba Medical Center has many years of experience in MICRA implants, which are performed at the Davidai Center for Rhythm Disturbances and Pacing at the Sheba Medical Center, managed by Prof. Roy Beinart. This week, the first training was held with the participation of seven doctors from several hospitals across Israel and led by Prof. Eyal Nof,
Director of the Invasive Electrophysiology Service at Sheba Medical Center and a certified facilitator to conduct training on the subject.

“As a medical center ranked among the top of the best hospitals in the world, we have made it our mission to lead the education and training of medical teams,” said Prof. Roy Beinart. “This project, the result of a collaboration with Medtronic, is part of that commitment. We will continue to provide the best medicine to our patients, using leading technologies such as MICRA and other innovations.” The MICRA is a tiny 2.5 cm rationing capsule, 93% smaller than a regular pacemaker, and implanted using a simple venous catheterization through the groin vein without leaving a scar on the chest. The system is implanted without additional devices in the body, unlike standard pacemakers which also require the implantation of electrodes that connect the heart compartments to the pacemaker.

The technology is currently intended for patients who, for technical or medical reasons, cannot undergo pacemaker implantation with electrodes (such as patients with venous obstruction). It is also suitable for patients with a high risk of infection from the implantation of a traditional pacemaker and without which they would be left without a medical
response which may put them at high risk of significant complications. Over the past year, more than 150 patients have undergone MICRA transplantation in various indications.
Clinical studies published in recent years, which included thousands of patients who underwent a MICRA transplant, showed that for the vast majority of patients, the MICRA transplant was successful, the rate of infections was significantly lower, and the rate of complications was significantly lower than that of a standard pacemaker transplant
(a reduction of about 60% in the rate of complications). In light of the results of the above publications and the positive global experience gained in the treatment with MICRA,
the European Cardiological Association (ESC) has recommended in its latest guidelines on pacemakers that MICRA should be implanted as an alternative to normal pacemakers in patients with appropriate indications.

About Sheba Medical Center

The largest and most comprehensive medical center in the Middle East, Sheba Medical Center, Tel Hashomer is generating global impact through its medical care, research and healthcare transformation. Sheba’s City of Health boasts an acute-care hospital, rehabilitation hospital, research and innovation hubs, medical simulation center and center for disaster response on one comprehensive campus in the center of Israel. A university teaching hospital
affiliated with the Sackler School of Medicine at Tel-Aviv University, Sheba is shaping the future of healthcare, educating the next generation of care providers. Sheba serves as a true hospital without borders, welcoming patients and healthcare professionals from all over the world and consistently providing the highest-level medical care to all in need.


Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form